Science and innovation in times of Covid-19 and policy responses



Policy Analyst, Directorate for Science, Technology and Innovation, OECD

IfTI Global Symposium – 16 September 2020





- 1 The short-term effects of the Covid-19 crisis on S&I
- 2 STI policy responses (as of September 2020)
- Longer-term opportunities and challenges for STI



The Covid-19 crisis has affected the entire science and innovation ecosystem



Quick **mobilisation** of R&D and innovation efforts to **address Covid-19**



Disruption in research & innovation activities of universities, research centres & businesses





1

Quick **mobilisation** of R&D and innovation efforts to **address Covid-19**

2

Disruption in research & innovation activities of universities, research centres & businesses






Large R&D efforts to address the Covid-19 health challenge

- Governments, foundations & industry (often in PPPs) have engaged in R&D efforts to develop Covid-19 **vaccines** (180 candidates in Sept 2020 35 in clinical evaluation), **treatments & diagnostics**
- Surge of scientific publications related to the virus

Number of drug therapies (all stages of development) in research pipelines, by disease



Source: Bryan, Lemus and Marshall (2020[2])



Open science & innovation initiatives have proliferated

Data sharing initiatives, e.g. <u>Covid-19</u> <u>Open Research Dataset (CORD-19)</u> with +50,000 machine-readable scholarly articles on Covid-19 and other coronaviruses



Online collaborative platforms, e.g.
 Coronavirusmakers with + 20,000 volunteer researchers, developers and engineers to produce emergency medical equipment



• **Distributed computing projects** that encourage citizens to donate their spare computing power to run complex modelling for Covid-19 research (e.g. Folding@home)





Innovators also mobilised to provide quick responses to the Covid-19 challenge

- Frugal innovations

 (e.g. ventilator masks built from snorkelling mask)
- Use of new digital tools

 (e.g. 3D-printing to produce respirator valves)
- Repurposing production lines (e.g. automotive & consumer goods manufacturers producing medical equipment & hand sanitizer)





1

Quick mobilisation of R&D and innovation efforts to address Covid-19

2

Disruption in research & innovation activities of universities, research centres & businesses





Universities and research institutions were highly disrupted by lockdown measures






- Interruption of projects requiring access to research facilities or involving field work & clinical trials
- Reduction in labour productivity, and risks of increased gender inequalities
- Restricted research mobility
- Disruption in human capital training
 & quick shift to online learning
- Diversion of research efforts towards Covid-19



Liquidity constraints and market uncertainty reduce business investments in R&I

- Many R&I projects are suspended or terminated
- Decline in number of investments in innovative start-ups (particularly earlystage venture capital)
- Lower market entry & more bankruptcies in Q1 & Q2 of 2020

Number of VC deals by investment stage, United Kingdom



Source: Ipsos Mori (2020) based on Pitchbook data

Reduction in businesses' **willingness to introduce new products** or processes in the short run...

... but the crisis (as past ones) **also offers opportunities** for some innovative businesses



Some actors benefitted from increased demand for some innovative (digital) products







- Teleworking tools
- Online shopping
- Video streaming & online gaming
- Online learning
- Telemedicine
- Cybersecurity

zoom









Innovation investments in those areas are likely to increase



- The short-term effects of the Covid-19 crisis on S&I
- 2 S&I policy responses (as of September 2020)
- Longer-term opportunities and challenges for S&I




Large amounts of funding for R&D have been mobilised at unprecedented speed

The US National Institutes of Health (NIH) spent **USD 1.8 billion** to Covid-19 research and the EU mobilised **EUR 1 billion** under Horizon 2020 (as of April/May 2020)

- Fast-track competitive research funding to develop Covid-19 vaccines, treatments & diagnostics
- Part of the support is channelled through existing funding mechanisms
- Some calls encourage existing grant holders to repurpose their research and innovation activities.





Source: ScienceBusiness, 2 June 2020

Note: The graph illustrates the number of published funding opportunities as of 22 May; it does not illustrate amounts of allocated funding. The full database reports more than 270 funding calls from 4 countries.



A diversity of policy instruments encourage quick innovation responses





Examples of fast-track open competitions

Fast-track open competitions Policy accelerate Covid-19 innovation

- Canada's <u>Covid-19 Challenge</u>
 <u>programme</u> posts specific challenges seeking near-to-market solutions from firms with less than 500 employees
- "Innovate for Italy", a fast call competition to identify best digital solutions available for telemedicine and monitoring applications for patients
- Ireland's COVID-19 Rapid Response
 Call
- <u>UK's fast-track competition for</u> business-led innovation



Examples of virtual hackathons



- <u>EUvsVirus Hackathon</u>, European
 Commission (April 2020), had +2,000
 solutions submitted and 117 winners
- #BuildforCOVID19 World Health
 Organisation with the support of technology
 firms
- MIT Covid19 Challenges
- Hack the crisis Accelerate Estonia and Garage 48
- <u>CoVent-19</u> Massachusetts General Hospital to design a rapidly deployable mechanical ventilator.



Measures to address immediate negative impacts of Covid-19 on innovative businesses

- Facilitate access to funding to entrepreneurs & innovative firms to mitigate liquidity problems, e.g.:
 - France: EUR 4 billion for Emergency Startup Relief Plan
 - Germany: EUR 2 billion to expand venture capital to support start-ups
- Support businesses (incl. SMEs) adapt to Covid-19 context, e.g.:
 - Ireland: Lean Business Continuity Vouchers & Business Improvement Grants





S&I policy responses to Covid-19 have raised some debates

1) Has research funding for Covid-19 vaccines and treatments been **appropriate?**

- Too much (e.g. Younes et al, 2020) vs not enough (e.g. Azoulay and Jones, 2020)
- Winner-take-all races and duplication of efforts?
- How to ensure global and fair access to solutions?



2) Have resources for S&I to address Covid-19 been **spent efficiently**?

- Possible duplications & insufficient quality in research efforts
- Speedy allocations risk rewarding "superstars" only but reduce diversity of contributions
- Funding agencies face operating challenges



- 1 The short-term effects of the Covid-19 crisis on STI
- 2 STI policy measures (as of September 2020)
- 3 Longer-term opportunities and challenges for STI



The longer-term impacts of Covid-19 on S&I are uncertain & will depend on characteristics of the recovery





1) Will the crisis accelerate the digitalisation of research and innovation?

AI applications at different stages of the Covid-19 crisis:

Detection **Early warning** Diagnosis Open data projects and distributed computing to find Al-driven solutions to the pandemic, e.g. drug and vaccine development Detecting anomalies and Pattern recognition using digital "smoke signals", medical imagery and symptom data, e.g. CT scans e.g. BlueDot **Information** Prevention Surveillance Prediction Personalised news and Accelerating research To monitor and track Calculating a person's content moderation to probability of infection, contagion in real time, fight misinformation, e.g. contact tracing e.g. EpiRisk e.g. via social networks Delivery Response Service automation Drones for materials' Deploying triaging virtual transport; robots for highassistants and chatbots, e.g. exposure tasks at hospitals, Canada's COVID-19 chatbot e.g. CRUZR robot Monitor Recovery Track economic recovery through satellite, GPS and social media data, e.g. WeBank



Positive experiences using digital technologies & services may accelerate business adoption






But **insufficient absorptive capacities** (skills), access to infastructure & financial resources for investments **may prevent** wider uptake



2) Will private R&D and innovation investments resist the business cycle?

The impact of the business cycle on business R&D investments, OECD countries



Note: BERD stands for Business expenditure on R&D.

Source: OECD (2020), "Main Science and Technology Indicators", OECD Science, Technology and R&D Statistics (database), https://doi.org/10.1787/data-00182/ and OECD (2020) "National Accounts at a Glance", OECD National Accounts Statistics (database), https://doi.org/10.1787/data-00369-en (accessed on 11 May 2020).



3) Will gaps across industries, regions and research institutions widen?

Unequal effects risk leaving lasting traces

- Unequal preparedness of businesses & research institutions to leverage digital tools
- Some **sectors** are severely hit (e.g. tourism, automotive) while others thrive during the crisis (digital sector)
- Possible reinforcement of large players at the expense of small players
- Gap may widen between leading universities and others


But some factors could reduce inequalities:

- Digital technologies & new work arrangements can contribute to more evenly spread innovation activities across regions ('the death of distance')
- **Incentive to reduce global concentration** of production to be less vulnerable to shocks (possible push back to globalisation)



4) What may be the impacts on S&I labour force?

Unemployment rate of tertiary educated, selected countries, 2005-18



Note: Age group 25-64.

Source: OECD (2020), "Education at a glance: Educational attainment and labour-force status", OECD Education Statistics (database), https://doi.org/10.1787/889e8641-en (accessed on 26 August 2020).



Future S&I policy will have to address a more complex set of policy goals



Economic growth & competitiveness



Resilience



Environmental sustainability



Inclusiveness

Complementarities & trade-offs

Thank you

Draft report

(updated version will be available soon): https://oe.cd/tip-covid19

OECD Survey

on STI policy responses to Covid-19: https://stip.oecd.org/Covid.html

OECD Digital Hub "Tackling the Coronavirus":

http://www.oecd.org/coronavirus/

Caroline Paunov, Caroline.Paunov@oecd.org

Sandra Planes-Satorra, Sandra.PlanesSatorra@oecd.org





